Medicine and Dentistry
Rapamycin
100%
Bladder Cancer
74%
Surgery
62%
T Cell
50%
Neoplasm
37%
Mechanistic Target of Rapamycin
37%
Patient
37%
Inpatient
37%
Low Drug Dose
25%
Exhaustion
25%
Metastatic Carcinoma
12%
Drug Megadose
12%
Antibody
12%
Prevalence
12%
Mammalian Target of Rapamycin Complex 1
12%
Phosphorylation
12%
Malignant Neoplasm
12%
Cystectomy
12%
Adverse Event
12%
Cell Growth
12%
Pharmacodynamics
12%
Tumor Progression
12%
Lung Metastasis
12%
Reduced Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone)
12%
Cell Metabolism
12%
Cellular Immunity
12%
Introspection
12%
Wound Complication
12%
Cancer Model
12%
Cancer Immunotherapy
12%
T Cell Activation
12%
T Cell Differentiation
12%
Bladder Tissue
12%
Blood
12%
Immunology and Microbiology
Sirolimus
100%
Bladder
74%
Immune Disorder
50%
Cell Growth
25%
Low Drug Dose
25%
Tumor Cell
25%
Mouse
25%
Monospecific Antibody
12%
Syngenic
12%
Drug Megadose
12%
Adoptive Immunity
12%
Blood Product
12%
Human
12%
Phosphorylation
12%
Cell Differentiation
12%
Prevalence
12%
Cancer Immunotherapy
12%
Cell Activation
12%
Pharmacodynamics
12%
Electric Potential
12%
Cell Metabolism
12%
Mammalian Target of Rapamycin Complex 1
12%
Introspection
12%
Immunity
12%
Bladder Tissue
12%
Pharmacology, Toxicology and Pharmaceutical Science
Rapamycin
100%
Bladder Cancer
74%
Neoplasm
37%
Mammalian Target of Rapamycin
37%
Mouse
25%
Exhaustion
25%
Programmed Death-Ligand 1
25%
Metastasis
12%
Prevalence
12%
Antibody
12%
Human
12%
Adverse Event
12%
Lung Metastasis
12%
Tumor Growth
12%
Malignant Neoplasm
12%
Cancer Model
12%
Reduced Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone)
12%
Mammalian Target of Rapamycin Complex 1
12%
Death
12%
Wound Complication
12%
Biochemistry, Genetics and Molecular Biology
Mechanistic Target of Rapamycin
37%
Low Drug Dose
25%
Cell Growth
25%
Mammalian Target of Rapamycin
25%
Mouse
25%
Phosphorylation
12%
Mammalian Target of Rapamycin Complex 1
12%
Cellular Immunity
12%
Cell Activation
12%
Cellular Differentiation
12%
Electric Potential
12%
Human
12%
Drug Megadose
12%
Prevalence
12%
Pharmacodynamics
12%
Cell Metabolism
12%
Syngenic
12%
PD-L1
12%
Cancer Immunotherapy
12%
Introspection
12%